Newly published data suggests most patients are opting for second- or third-generation tyrosine kinase inhibitors instead of a generic form of imatinib. Patients with chronic myelogenous leukemia (CML ...

Chronic myelomonocytic leukemia (CMML) and chronic myeloid leukemia (CML) are two types of cancers that affect the blood and bone marrow. In both types, certain blood cells multiply out of control.

Initial discussions about treatment, side effects and study results can help patients navigate through all aspects of a chronic myeloid leukemia diagnosis. The initial discussions with health care ...

Genetic testing for chronic myeloid leukemia (CML) can tell doctors if someone has leukemia, what type they may have, and whether treatment is working. The tests look for atypical changes in certain ...

Add Yahoo as a preferred source to see more of our stories on Google. New year, new authors are visiting the Columbus Metropolitan Library (CML). After introducing the revamped Authors at the Library ...

With recent advances, treatment for chronic myeloid leukemia (CML) can often slow or stop the progression of the disease. Today, CML may be treated similarly to a chronic long-term condition. The goal ...

The life expectancy of patients with recently diagnosed chronic myeloid leukemia (CML) is now approaching that of the general population, which is an important message for physicians to convey to ...

LONDON--(BUSINESS WIRE)--The global chronic myelogenous leukemia (CML) therapeutics market size is poised to grow by USD 1.74 billion during 2019-2023, according to a new report by Technavio, ...

Novartis is in Chicago for the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting and has brought along an interactive experience for the weekend. The Swiss drugmaker is rolling out its ...

Please provide your email address to receive an email when new articles are posted on . It has been eight years since imatinib was approved as the first oral tyrosine kinase inhibitor indicated for ...